Journal
SCHIZOPHRENIA BULLETIN
Volume 49, Issue 4, Pages 881-892Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbac175
Keywords
treatment-resistant psychosis; copy number variants; ultra-TRS; 16p11.2 duplication; 15q 11.2-q 13.1 duplication; schizophrenia; neurodevelopmental disorders; rare variants
Categories
Ask authors/readers for more resources
This study investigates the relationship between copy number variants (CNVs) and treatment-resistant psychosis in patients with psychotic disorders. It suggests that CNVs, especially those associated with neurodevelopmental risk, may impact treatment resistance and serve as biological markers for studying this condition.
Background: It remains unknown why similar to 30% of patients with psychotic disorders fail to respond to treatment. Previous genomic investigations of treatment-resistant psychosis have been inconclusive, but some evidence suggests a possible link between rare disease-associated copy number variants (CNVs) and worse clinical outcomes in schizophrenia. Here, we identified schizophrenia-associated CNVs in patients with treatment-resistant psychotic symptoms and then compared the prevalence of these CNVs to previously published schizophrenia cases not selected for treatment resistance. Methods: CNVs were identified using chromosomal microarray (CMA) and whole exome sequencing (WES) in 509 patients with treatment-resistant psychosis (a lack of clinical response to >= 3 adequate antipsychotic medication trials over at least 5 years of psychiatric hospitalization). Prevalence of schizophrenia-associated CNVs in this sample was compared to that in a previously published large schizophrenia cohort study. Results: Integrating CMA and WES data, we identified 47 cases (9.2%) with at least one CNV of known or possible neuropsychiatric risk. 4.7% (n = 24) carried a known neurodevelopmental risk CNV. The prevalence of well-replicated schizophrenia-associated CNVs was 4.1%, with duplications of the 16p11.2 and 15q11.2-q13.1 regions, and deletions of the 22q11.2 chromosomal region as the most frequent CNVs. Pairwise loci-based analysis identified duplications of 15g11.2-813.1 to be independently associated with treatment resistance. Conclusions: These findings suggest that CNVs may uniquely impact clinical phenotypes beyond increasing risk for schizophrenia and may potentially serve as biological entry points for studying treatment resistance. Further investigation will be necessary to elucidate the spectrum of phenotypic characteristics observed in adult psychiatric patients with disease-associated CNVs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available